322 related articles for article (PubMed ID: 11874218)
1. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
2. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
3. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
5. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt ER; Russell JM; Miceli R; Colucci SV; Xu Y; Grudzinski AN
Value Health; 2000; 3(3):208-21. PubMed ID: 16464185
[TBL] [Abstract][Full Text] [Related]
6. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Shih YC; Bekele NB; Xu Y
Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
Panzarino PJ; Xuan J
Manag Care Interface; 2001 Apr; 14(4):59-65. PubMed ID: 11339023
[TBL] [Abstract][Full Text] [Related]
8. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.
Sclar DA; Robison LM; Skaer TL; Galin RS; Legg RF; Nemec NL; Hughes TE; Buesching DP; Morgan M
J Int Med Res; 1995; 23(6):395-412. PubMed ID: 8746607
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Serrano-Blanco A; Pinto-Meza A; Suárez D; Peñarrubia MT; Haro JM;
Acta Psychiatr Scand Suppl; 2006; (432):39-47. PubMed ID: 17087814
[TBL] [Abstract][Full Text] [Related]
11. Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Nurnberg HG; Hensley PL; Thompson PM; Paine SS
Psychiatr Serv; 1999 Oct; 50(10):1351-3. PubMed ID: 10506306
[TBL] [Abstract][Full Text] [Related]
12. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
13. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
14. Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs.
Sabin JE; Daniels N
Psychiatr Serv; 2003 Oct; 54(10):1343-4,1349. PubMed ID: 14557518
[No Abstract] [Full Text] [Related]
15. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
17. The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
Roy-Byrne PP; Clary CM; Miceli RJ; Colucci SV; Xu Y; Grudzinski AN
J Clin Psychiatry; 2001 Sep; 62(9):678-82. PubMed ID: 11681762
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cost savings to a state Medicaid program following a sertraline tablet-splitting program.
Vuchetich PJ; Garis RI; Jorgensen AM
J Am Pharm Assoc (2003); 2003; 43(4):497-502. PubMed ID: 12952314
[TBL] [Abstract][Full Text] [Related]
19. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Dewa CS; Hoch JS; Goering P
Clin Ther; 2001 Feb; 23(2):292-306. PubMed ID: 11293562
[TBL] [Abstract][Full Text] [Related]
20. Are paroxetine, fluoxetine, and sertraline equally effective for depression?
Straton JB; Cronholm P
J Fam Pract; 2002 Mar; 51(3):285. PubMed ID: 11978244
[No Abstract] [Full Text] [Related]
[Next] [New Search]